Inflammatory bowel disease (IBD) is an ongoing or chronic health problem that causes inflammation and swelling in the digestive tract. The irritation causes bleeding sores called ulcers to form along the digestive tract. This in turn can cause crampy, abdominal pain and severe bloody diarrhea.
There are two main types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). The diseases are very similar. In fact, doctors often have a hard time figuring out which type of IBD a person has. The main difference between UC and CD is the area of the digestive tract they affect. CD can occur along the entire digestive tract and spread deep into the bowel wall. In contrast, UC usually only affects the top layer of the large intestine (colon) and rectum. Medicine can control the symptoms of IBD in most women. But for people who have severe IBD, surgery is sometimes needed. Over the course of a person's life, the symptoms of IBD often come and go. With close monitoring and medicines, most people with IBD lead full and active lives.
Well, the central dogma of biology states that DNA makes RNA and RNA makes proteins. However, there are many different types of RNAs, and only one of them, the messenger RNA (mRNA), gives rise to proteins. Some others don't make proteins at all.
Using international genomic studies backed by proof-of-concept cell experiments, researchers have identified two genes that contribute to the chronic kidney disease glomerulonephritis.
Beneficial bacteria may be the key to helping to reverse a cycle of gut inflammation seen in certain inflammatory bowel diseases, University of North Carolina Lineberger Comprehensive Cancer Center researchers have found.
The capacity for memory isn't exclusive to the brain. The immune system, with its sprawling network of diverse cell types, can recall the pathogens it meets, helping it to swiftly neutralize those intruders upon future encounters.
Specific cells in the retina trigger inflammation and vision impairment associated with diabetes, according to new research out of Case Western Reserve University School of Medicine.
The diagnosis, understanding and management of Crohn's disease may have just received a helping hand from a joint ASU Biodesign Institute and Mayo Clinic study aimed at developing a better blood test for the disease.
During the past decade, the gut has experienced a renaissance as investigations focus on the role of the microbiome on human health.
Using red blood cells modified to carry disease-specific antigens, scientists in the laboratories of Hidde Ploegh and Harvey Lodish have prevented and alleviated two autoimmune diseases—multiple sclerosis (MS) and type 1 diabetes—in early stage mouse models.
Researchers have uncovered new genetic clues to understanding IgA nephropathy (IgAN), or Berger's disease, an autoimmune kidney disease and a common cause of kidney failure.
Natural health experts BetterYou have welcomed a recommendation by leading gastroenterology expert Isobel Mason, to take a vitamin D supplement to reduce Crohn’s flare-ups.
New research indicates that the incidence of inflammatory bowel disease-including ulcerative colitis (UC) and Crohn's disease (CD)-in Denmark is on the rise and is among the highest in the world.
Institute scientists have revealed a potent inflammatory molecule released by dying cells triggers inflammation during necroptosis, a recently described form of cell death linked to inflammatory disease.
The 12th ECCO Congress that took place in Barcelona, Spain, from 15 to 18 February 2017, was an excellent opportunity for Vifor Pharma to continue its support of healthcare efforts and to highlight the detrimental impact of iron deficiency, a particularly common condition in people with certain chronic diseases such as inflammatory bowel disease (IBD).
A new study led by researchers at Beth Israel Deaconess Medical Center has found that lower levels of vitamin D in the blood increase the risk of clinical relapse in patients with Ulcerative Colitis, an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the colon.
New research shows that nearly three-quarters of patients with moderate to severe ulcerative colitis (UC) taking conventional treatments describe their disease as ‘poorly controlled’ (continuous or regular experience of symptoms that negatively affect quality of life), with half saying they are somewhat or completely dissatisfied with their current medication; only 1% were completely satisfied with their current treatment.
The discovery of the 'molecular switch' that causes inflammatory bowel disease (IBD) and Celiac disease, could lead to more effective new treatments for these life-changing auto-immune conditions, according to research from scientists at King's College London and University College London.
The human gut is home to some 100 trillion bacteria, comprising between 250 and 500 species. This astounding array of organisms, collectively known as the gut microbiome, is a powerful regulator of disease and health and has been implicated in conditions ranging from inflammatory bowel disease to multiple sclerosis.
Patients with inflammatory bowel disease are more likely to see dramatic shifts in the make-up of the community of microbes in their gut than healthy people, according to the results of a study published online Feb. 13 in Nature Microbiology.
Patients with Crohn's disease, a type of inflammatory bowel disease (IBD) that causes abdominal pain and diarrhea, can also experience joint pain.
A study led by UT Southwestern Medical Center researchers has uncovered key molecular pathways behind the disruption of the gut's delicate balance of bacteria during episodes of inflammatory disease.